Grail Seeks to Raise $1B in Series B; Illumina's Stake to Fall Below 20 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Illumina's liquid biopsy startup Grail is aiming to raise $1 billion in its Series B financing round, Illumina said after the close of the market on Thursday.

The $1 billion would be raised from undisclosed private and strategic investors, from which Grail has received interest, Illumina said. Grail said that it has tapped Goldman Sachs to serve as a placement agent for additional financing in plans to raise in its Series B round, which it will close before the end of the first quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.